Location History:
- Heemstede, NL (2006 - 2015)
- BH Heemstede, NL (2015 - 2018)
Company Filing History:
4 out of 11 
3 out of 97 
Years Active: 2006-2018
Title: Frank Pieper: Innovator in Pharmaceutical Composition and Ischemia-Reperfusion Injury Treatment
Introduction
Frank Pieper is a notable inventor based in Heemstede, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of bleeding and ischemia-reperfusion injuries. With a total of seven patents to his name, Pieper's work has the potential to impact medical practices significantly.
Latest Patents
One of Frank Pieper's latest patents is focused on the treatment of bleeding with low half-life fibrinogen. This invention involves a pharmaceutical composition of recombinant human fibrinogen that has a half-life of less than 12 hours, combined with a pharmaceutically acceptable carrier or diluent. The composition may also include factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin, along with divalent metal cations. Another significant patent addresses the use of C1 inhibitor for the prevention of ischemia-reperfusion injury. This invention highlights the therapeutic and prophylactic use of C1 inhibitor to prevent, reduce, and treat ischemia and reperfusion injury, proving effective even when administered after an ischemic period.
Career Highlights
Throughout his career, Frank Pieper has worked with prominent companies in the biotechnology and pharmaceutical sectors. Notable among these are Pharming Intellectual Property B.V. and Laboratoire Français Du Fractionnement Et Des Biotechnologies. His work in these organizations has contributed to advancements in medical treatments and therapies.
Collaborations
Frank Pieper has collaborated with esteemed colleagues, including Maurice Mannesse and Johannes Henricus Nuijens. These partnerships have fostered innovation and development in the field of pharmaceuticals.
Conclusion
Frank Pieper's contributions to pharmaceutical innovations, particularly in the treatment of bleeding and ischemia-reperfusion injuries, underscore his importance as an inventor. His patents reflect a commitment to advancing medical science and improving patient outcomes.